文献速递胸部CT

基于CT的影像组学特征可预测非小细胞肺癌患者一线化疗和靶向治疗的肿瘤反应

CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy.
PubMed 文献 · Eur Radiol · 2021-09-26

本研究回顾性纳入322例接受一线化疗、靶向治疗或联合治疗的非小细胞肺癌患者,从治疗前CT图像提取1946个影像组学特征,构建随机森林分类器模型预测肿瘤反应。初始轻量级特征模型AUC为0.721(95%CI 0.619-0.823),进一步筛选6个独立预测特征后精炼模型AUC提升至0.746(95%CI 0.646-0.846)。结论认为基于治疗前CT的影像组学特征可较准确预测NSCLC患者一线治疗后的肿瘤反应。

要点

  • 治疗前CT影像组学特征可预测NSCLC一线化疗/靶向治疗的肿瘤反应,精炼模型AUC为0.746。
  • 特征筛选采用MRMR方法,最终模型基于6个独立预测特征(AUC>0.6,p<0.05)构建。
  • 影像组学特征有望作为预后影像生物标志物,辅助治疗决策和个体化治疗。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The goal of this study was to evaluate the effectiveness of radiomics signatures on pre-treatment computed tomography (CT) images of lungs to predict the tumor responses of non-small cell lung cancer (NSCLC) patients treated with first-line chemotherapy, targeted therapy, or a combination of both.

MATERIALS AND METHODS: This retrospective study included 322 NSCLC patients who were treated with first-line chemotherapy, targeted therapy, or a combination of both. Of these patients, 224 were randomly assigned to a cohort to help develop the radiomics signature. A total of 1946 radiomics features were obtained from each patient's CT scan. The top-ranked features were selected by the Minimum Redundancy Maximum Relevance (MRMR) feature-ranking method and used to build a lightweight radiomics signature with the Random Forest (RF) classifier. The independent predictive (IP) features (AUC > 0.6, p value < 0.05) were further identified from the top-ranked features and used to build a refined radiomics signature by the RF classifier. Its prediction performance was tested on the validation cohort, which consisted of the remaining 98 patients.

RESULTS: The initial lightweight radiomics signature constructed from 15 top-ranked features had an AUC of 0.721 (95% CI, 0.619-0.823). After six IP features were further identified and a refined radiomics signature was built, it had an AUC of 0.746 (95% CI, 0.646-0.846).

CONCLUSIONS: Radiomics signatures based on pre-treatment CT scans can accurately predict tumor response in NSCLC patients after first-line chemotherapy or targeted therapy treatments. Radiomics features could be used as promising prognostic imaging biomarkers in the future.

KEY POINTS: The radiomics signature extracted from baseline CT images in patients with NSCLC can predict response to first-line chemotherapy, targeted therapy, or both treatments with an AUC = 0.746 (95% CI, 0.646-0.846). The radiomics signature could be used as a new biomarker for quantitative analysis in radiology, which might provide value in decision-making and to define personalized treatments for cancer patients.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yang F, Zhang J, Zhou L, et al. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy. Eur Radiol. 2021. PMID: 34564744. doi:10.1007/s00330-021-08277-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。